Buemi M, Allegra A, Aloisi C, Frisina N
Chair of Nephrology II, Messina University, Italy.
Am J Nephrol. 1991;11(4):281-3. doi: 10.1159/000168322.
The authors wished to investigate some aspects of the cell-mediated immunity in hemodialyzed subjects undergoing a treatment with recombinant erythropoietin (rHuEPO). The study was carried out through the dosage of the serum levels of neopterin, a substance produced by the macrophages and usable as a marker of their state of activation. The results show a significant reduction of the serum levels of pteridine already at the second month of treatment with rHuEPO (61 +/- 9 vs. 95 +/- 12 nmol/l), thus proving a probable inhibitory action carried out by erythropoietin on certain cells of the immune system.
作者希望研究接受重组促红细胞生成素(rHuEPO)治疗的血液透析患者细胞介导免疫的某些方面。该研究通过测定血清中新蝶呤的水平来进行,新蝶呤是一种由巨噬细胞产生的物质,可用作其激活状态的标志物。结果显示,在使用rHuEPO治疗的第二个月,血清蝶啶水平就显著降低(61±9 vs. 95±12 nmol/l),从而证明促红细胞生成素可能对免疫系统的某些细胞产生抑制作用。